# A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL

> **NCT07723911** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 212 (estimated)

## Conditions studied

- Precursor B-cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** BLB101 for Injection
- **DRUG:** Blinatumomab for Injection

## Key facts

- **NCT ID:** NCT07723911
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-09
- **Primary completion:** 2027-10-10
- **Final completion:** 2028-10-10
- **Target enrollment:** 212 (ESTIMATED)
- **Last updated:** 2026-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07723911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07723911, "A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07723911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*